News from merck kgaa A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

May 15, 2019, 18:43 ET Merck KGaA, Darmstadt, Germany Data at ASCO 2019 Showcase Multiple Innovative Molecules with Potential to Impact Unmet Needs in Cancer Care

Not intended for UK-based media ASCO Abstract # Bintrafusp alfa (bifunctional fusion protein): TPS9114; Tepotinib (MET kinase inhibitor): 9005;...


Mar 19, 2019, 19:15 ET Merck KGaA, Darmstadt, Germany, and Pfizer Announce Discontinuation of Phase III JAVELIN Ovarian PARP 100 Trial in Previously Untreated Advanced Ovarian Cancer

Not intended for UK-based media Merck KGaA, Darmstadt, Germany, which operates its biopharmaceutical business as EMD Serono in the US and Canada, and ...


Feb 16, 2019, 17:14 ET Pivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of Medicine

JAVELIN Renal 101 shows significant improvement in progression-free survival with a hazard ratio of 0.69 in patients regardless of PD-L1 expression...


Feb 05, 2019, 07:21 ET Merck KGaA, Darmstadt, Germany and GSK Announce Global Alliance to Jointly Develop and Commercialize M7824, a Novel Immunotherapy with Potential in Multiple Difficult-to-Treat Cancers

Merck KGaA, Darmstadt, Germany, a leading science and technology company and GSK, a science-led global healthcare company, today announced that the...


Dec 10, 2018, 10:00 ET Merck KGaA, Darmstadt, Germany Announces FDA Orphan Drug Designation for Bifunctional Immunotherapy M7824 in Biliary Tract Cancer

The information contained is not intended for distribution in the UK FDA grants M7824, an investigational bifunctional immunotherapy, orphan drug...


Oct 10, 2018, 02:00 ET Up to 10-Years of Follow-up Data Reaffirm Safety Profile of Investigational Cladribine Tablets

Real-world evidence and longer clinical trial follow-up show no increased incidence of serious adverse events Additional post-hoc data analyses...


Oct 08, 2018, 06:00 ET New Efficacy and Safety Data on MS Portfolio to Be Presented at ECTRIMS 2018

Late-breaking Phase II primary endpoint data for investigational therapy evobrutinib, the first oral BTK inhibitor to show clinical proof-of-concept...


Jun 18, 2018, 06:00 ET Data Provide Further Insight Into the Consistent Efficacy Benefits of Mavenclad in Relapsing MS

Not intended for U.S or U.K based media Post-hoc analysis of CLARITY study suggests consistent clinical and Magnetic Resonance Imaging efficacy in...


Jun 14, 2018, 09:00 ET Merck to Present Data on Mavenclad® and Rebif® in Relapsing Forms of Multiple Sclerosis at EAN

Merck, a leading science and technology company, will present data from its neurology and immunology portfolio at the 4th Congress of the European...


Jun 04, 2018, 08:00 ET Two-Year Update of Pivotal JAVELIN Merkel 200 Trial Shows Continued Durable Responses with BAVENCIO® (avelumab)

Not intended for UK-based media Two-year follow-up data on meaningful durable responses, overall survival (OS) and progression-free survival (PFS) to ...


May 17, 2018, 12:10 ET Merck Data at ASCO 2018 to Showcase Progress and Further Optionality of Oncology Pipeline

Not intended for UK- or US-based media ASCO Abstract # ERBITUX® (cetuximab): 3521, 3534, e15711; avelumab: 9507, 9537, 9090, 9008, 8563, 3057, 4544,...


May 16, 2018, 09:13 ET Merck KGaA, Darmstadt, Germany Data at ASCO 2018 to Showcase Progress and Further Optionality of Oncology Pipeline

Not intended for UK-based media ASCO Abstract # Avelumab: 9507, 9537, 9090, 9008, 8563, 3057, 4544, e21531, e13603, e18932, e21623, e21620, e21544;...


Nov 13, 2017, 03:15 ET Merck und International Diabetes Federation widmen sich gemeinsam dem Kampf gegen die globale Typ-2-Diabetes-Epidemie

Im Fokus der Partnerschaft stehen Initiativen zur Schulung und Bewusstseinsbildung mit dem Ziel der Prävention von Typ-2-Diabetes Onlinekurs für...


Sep 27, 2017, 04:00 ET Bavencio (avelumab) Approved for Merkel Cell Carcinoma in Japan

Not intended for UK-based media First-ever treatment indicated for curatively unresectable Merkel cell carcinoma (MCC) and first anti-PD-L1 to be...


Sep 11, 2017, 06:57 ET Merck KGaA, Darmstadt, Germany, Set to Join Forces with Project Data Sphere to Pioneer Global Oncology Big Data Alliance

Not intended for U.K. based media Big data platform to help accelerate innovative discovery, development and delivery of new approaches in cancer...


Sep 10, 2017, 15:00 ET Merck KGaA, Darmstadt, Germany, ‘Grant for Oncology Innovation’ Awards Recognize Recipients for Pushing Boundaries in Oncology Research

Not intended for UK-based media €1 million grant funded by Merck KGaA, Darmstadt, Germany, supports research with the potential to advance...


Sep 10, 2017, 15:00 ET Merck 'Grant for Oncology Innovation' Awards Recognize Recipients for Pushing Boundaries in Oncology Research

Not intended for UK/U.S. based media €1 million grant funded by Merck supports research with the potential to advance implementation of personalized...


Aug 30, 2017, 18:41 ET Merck: Driving Innovation in Cancer Care at ESMO 2017 With New Data in Hard-to-Treat Cancers

Not intended for U.K. or U.S. based media ESMO 2017 abstract # Erbitux®: 576P, 593P, 1068P, 1579P; avelumab: 1227P, 913P, 1377TiP, 882P, 856P; M6620...


Aug 30, 2017, 18:10 ET Merck KGaA, Darmstadt, Germany: Driving Innovation in Cancer Care at ESMO 2017 With New Data in Hard-to-Treat Cancers

Not intended for UK-based media Data to showcase Merck KGaA, Darmstadt, Germany's strong and diverse pipeline ranging from immuno-oncology to DNA...


Aug 01, 2017, 11:05 ET Opinión positiva del CHMP de la EMA sobre el uso de avelumab para el tratamiento del carcinoma de células de Merkel metastásico

De ser aprobado, avelumab podría ser el primer tratamiento de inmunoterapia indicado para este raro y agresivo tipo de cáncer de piel en Europa Se...


Jul 05, 2017, 04:22 ET Merck KGaA, Darmstadt, Germany Awards €1.25 Million to Research Projects Through its 2017 Grant for Fertility Innovation (GFI)

Two projects are awarded funds to advance the fertility field Professor Lunenfeld honored with Merck KGaA, Darmstadt, Germany Lifetime Achievement...


Mar 30, 2017, 02:00 ET Merck KGaA, Darmstadt, Germany Advances R&D Strategy through Unique Development Model with Avillion for Anti IL-17 A/F Nanobody®

Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced a development agreement with Avillion, a UK-based company...


Mar 02, 2017, 01:00 ET NICE Expands Positive Recommendation for Erbitux as First-line Treatment for RAS Wild-type mCRC

Not intended for UK- or US-based media More patients now able to receive a standard-of-care treatment with Erbitux plus FOLFIRI or FOLFOX NICE's...


Nov 18, 2016, 08:00 ET Merck KGaA, Darmstadt, Germany's Massachusetts-based Businesses Named 'Top Places to Work' by The Boston Globe

Merck KGaA, Darmstadt, Germany today announced that its Massachusetts-based businesses have been named to The Boston Globe's annual "Top Places to...


Sep 14, 2016, 08:00 ET Merck KGaA, Darmstadt, Germany, Joins DiViNe Consortium to Address Low Yields, High Costs of Vaccine Purification Processes

Merck KGaA, Darmstadt, Germany, a leading science and technology company, has joined the DiViNe project, a European consortium of six companies to...